Suppr超能文献

评估延长使用度吡非尼酮和左炔诺孕酮阴道环的安全性、药代动力学和与阴道出血相关的 1 期随机试验。

Phase 1 randomized trials to assess safety, pharmacokinetics, and vaginal bleeding associated with use of extended duration dapivirine and levonorgestrel vaginal rings.

机构信息

Department of Obstetrics, Gynecology, and Reproductive Sciences, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America.

Magee-Womens Research Institute, Pittsburgh, Pennsylvania, United States of America.

出版信息

PLoS One. 2024 Jun 5;19(6):e0304552. doi: 10.1371/journal.pone.0304552. eCollection 2024.

Abstract

BACKGROUND

Vaginal rings formulated to deliver two drugs simultaneously have potential as user-controlled, long-acting methods for dual prevention of HIV and pregnancy.

METHODS

Two phase 1 randomized trials (MTN-030/IPM 041 and MTN-044/IPM 053/CCN019) respectively enrolled 24 and 25 healthy, HIV-negative participants to evaluate safety, pharmacokinetics, and vaginal bleeding associated with use of a vaginal ring containing 200mg dapivirine (DPV) and 320mg levonorgestrel (LNG) designed for 90-day use. MTN-030/IPM 041 compared the DPV/LNG ring to a DPV-only ring (200mg) over 14 days of use. MTN-044/IPM 053/CCN019 compared continuous or cyclic use of the DPV/LNG ring over 90 days of use. Safety was assessed by recording adverse events (AEs). DPV and LNG concentrations were quantified in plasma, cervicovaginal fluid, and cervical tissue. Vaginal bleeding was self-reported.

RESULTS

There were no differences in the proportion of participants with grade ≥2 genitourinary AEs or grade ≥3 AEs with DPV/LNG ring vs. DPV ring use (p = .22), or with DPV/LNG ring continuous vs. cyclic use (p = .67). Higher plasma DPV concentrations were observed in users of DPV/LNG compared to DPV-only rings (Cmax p = 0.049; AUC p = 0.091). Plasma DPV and LNG concentrations were comparable with continuous and cyclic use (Cmax p = 0.74; AUC p = 0.25). With cyclic use, median nadir plasma DPV concentration was approximately 300 pg/mL two days after removal and median t1/2 for cervicovaginal fluid DPV concentration was 5.76 hours (n = 3). Overall bleeding experiences did not differ between continuous and cyclic users (p = 0.12).

CONCLUSIONS

The extended duration DPV/ LNG rings were well tolerated and the observed DPV concentrations in plasma and cervicovaginal fluid when used continuously exceeded concentrations observed in previous DPV ring efficacy studies. LNG concentrations in plasma were comparable with other efficacious LNG-based contraceptives. Genital DPV concentrations had a short half-life and were thus not well sustained following ring removal.

摘要

背景

同时递送两种药物的阴道环作为一种使用者控制的长效方法,具有预防 HIV 和妊娠的双重潜力。

方法

两项 1 期随机试验(MTN-030/IPM 041 和 MTN-044/IPM 053/CCN019)分别招募了 24 名和 25 名健康、HIV 阴性的参与者,以评估含有 200mg 地匹福林(DPV)和 320mg 左炔诺孕酮(LNG)的阴道环的安全性、药代动力学和与使用相关的阴道出血,该阴道环设计用于 90 天使用。MTN-030/IPM 041 将 DPV/LNG 环与使用 14 天的仅含 DPV 环(200mg)进行了比较。MTN-044/IPM 053/CCN019 将 DPV/LNG 环的连续或周期性使用与 90 天的使用进行了比较。通过记录不良事件(AE)来评估安全性。在血浆、宫颈阴道分泌物和宫颈组织中定量检测 DPV 和 LNG 浓度。阴道出血由自我报告。

结果

使用 DPV/LNG 环与使用 DPV 环的参与者中,≥2 级泌尿生殖系统 AE 或≥3 级 AE 的比例(p =.22)或 DPV/LNG 环连续与循环使用(p =.67)无差异。与仅含 DPV 环相比,使用 DPV/LNG 环的患者血浆中 DPV 浓度更高(Cmax p = 0.049;AUC p = 0.091)。血浆 DPV 和 LNG 浓度与连续和循环使用相当(Cmax p = 0.74;AUC p = 0.25)。在循环使用中,在取出后两天,中位血浆 DPV 浓度的最低值约为 300pg/ml,中位宫颈阴道分泌物 DPV 浓度半衰期为 5.76 小时(n = 3)。连续使用者和循环使用者的总体出血经历无差异(p = 0.12)。

结论

延长持续时间的 DPV/LNG 环具有良好的耐受性,当连续使用时,观察到的血浆和宫颈阴道分泌物中的 DPV 浓度高于先前 DPV 环疗效研究中观察到的浓度。血浆中 LNG 浓度与其他有效的 LNG 为基础的避孕药具相当。阴道内 DPV 浓度半衰期短,因此环取出后不能很好地维持。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c406/11152307/b0321a6a0b4d/pone.0304552.g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验